|Security||JCS / Communications Systems, Inc. (203900105)|
|CEO||Lacey Roger HD|
|Industry||Telephone and Telegraph Apparatus|
|Institutional Shares||2,908,661 - 31.79%|
|Common Shares Outstanding||9,149,924 shares (as of 2018-06-30)|
|Institutional Value||$ 11,173,000 USD|
Institutional Stock Ownership and Shareholders
Communications Systems, Inc. (NASDAQ:JCS) has 30 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2,908,661 shares.
Largest shareholders include
Gamco Investors, Inc. Et Al, Dimensional Fund Advisors Lp, Renaissance Technologies LLC, Gabelli Funds Llc, Vanguard Group Inc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Ancora Advisors, LLC, Bridgeway Capital Management Inc, and Gould Asset Management Llc /ca/.
Communications Systems, Inc. (NASDAQ:JCS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|GABELLI FUNDS LLC||390,000||391,416||0.36||1,470||1,491||1.43|
|SCHWAB CHARLES INVESTMENT MANAGEMENT INC||53,328||0||-100.00||196||0||-100.00|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||14,540||13,251||-8.87||53||50||-5.66|
|MACQUARIE GROUP LTD||30,230||22,030||-27.13||114||84||-26.32|
|GAMCO INVESTORS, INC. ET AL||695,110||675,104||-2.88||2,620||2,572||-1.83|
|AMERIPRISE FINANCIAL INC||22,277||27,293||22.52||84||104||23.81|
|Ancora Advisors, LLC||98,298||102,004||3.77||371||389||4.85|
|DIMENSIONAL FUND ADVISORS LP||498,489||473,911||-4.93||1,829||1,806||-1.26|
|BRIDGEWAY CAPITAL MANAGEMENT INC||148,600||83,900||-43.54||545||320||-41.28|
|PANAGORA ASSET MANAGEMENT INC||9,273||6,030||-34.97||34||23||-32.35|
|BREMER TRUST NATIONAL ASSOCIATION||16,150||16,150||0.00||61||62||1.64|
|BlackRock Investment Management, LLC||1,353||1,353||0.00||6||6||0.00|
|Fny Investment Advisers, Llc||45||0|
|NORTHERN TRUST CORP||23,118||23,218||0.43||87||88||1.15|
|GEODE CAPITAL MANAGEMENT, LLC||26,093||26,283||0.73||95||100||5.26|
|Advisornet Financial, Inc||1,010||10||-99.01||4||0||-100.00|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||26,400||26,400||0.00||97||101||4.12|
|ROYAL BANK OF CANADA||5,720||5,720||0.00||22||22||0.00|
|UBS Group AG||4,383||1,163||-73.47||17||4||-76.47|
|VANGUARD GROUP INC||159,922||214,622||34.20||587||818||39.35|
|Tower Research Capital LLC (TRC)||0||1,676||0||6|
|WELLS FARGO & COMPANY/MN||0||1||0||0|
|DEUTSCHE BANK AG\||15,665||25,038||59.83||59||95||61.02|
|GOULD ASSET MANAGEMENT LLC /CA/||28,138||29,008||3.09||106||111||4.72|
|Renaissance Technologies LLC||445,265||1,678|
|Alpha Cubed Investments, LLC||23,044||88|
|Resources Investment Advisors, Inc.||252||0||-100.00||1||0||-100.00|
|BlackRock Institutional Trust Company, N.A.||109,771||109,771||0.00||523||508||-2.87|
|BlackRock Fund Advisors||22,331||23,085||3.38||106||107||0.94|
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
The company is growing revenues in the high single digits and undergoing structural changes to streamline business units and better position for growth.
The share price is approaching fair value levels and there is only about 6% of upside from current share levels.
Good day, and welcome to the Ultralife Corporation Second Quarter 2018 Earnings Conference Call. At this time, for opening remarks and introduction, I'd like to turn the call over to Ms. Jody Burfening. Please go ahead.
Greetings, and welcome to the Harris Corporation Fourth Quarter Fiscal Year 2018 Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded.
Michael Cohen wasn't the only one with ties to President Donald Trump trying to rope in billion-dollar companies. Former campaign advisors at Avenue Strategies were doing the same — with broader reach and apparently much more success. (1-0)
Good day, and welcome to this Ultralife Corporation First Quarter 2018 Earnings Release Conference Call. This call is being recorded. At this time, for opening remarks and introductions, I'd like to turn the call over to Jody Burfening. Please go ahead, ma'am. (3-0)
as of ET